RSH’s cutting-edge technology, combined with Kindeva’s CDMO capabilities, will supercharge the product journey as RSH prepares for commercial readiness.
The non-exclusive agreement will see Kindeva and RSH identify partners for the development of the "RSH Olfactory Delivery Device," a dual nostril intranasal platform used to precisely target specific regions of the nasal cavity.
The device can deposit the majority of a drug dose into the olfactory clefts. The Olfactory Clefts are both a desirable target for drug deposition and, yet, historically are a difficult location to reach because of the complex human nasal anatomy.
Early research suggests the device has the potential to achieve high deposition by ejecting a laminar stream when compared with conventional intranasal treatments that eject a plume spray or mist.
Further, the RSH technology overcomes complex nasal anatomy through the device’s proprietary dispensing tips that extend past the nasal valve to an optimal vantage point.
Another feature of the RSH technology that sets it apart is attention to human factors to ensure the device is accessible, comfortable, and easy to use correctly for accurate dosing, especially among cognitively and or physically impaired patients, and for self-administration.
Kenneth Irving, Rocket Science Health’s founder and CEO, said of the news: “A personal experience with an unreliable delivery method opened my eyes to the influence of drug devices on health outcomes."
"That realisation led to the founding of Rocket Science Health and nearly a decade of rethinking intranasal delivery. Knowing subregions of the nasal cavity provide access to different organ systems, most notably the CNS via the olfactory clefts, we redesigned the fluidics and user experience to enable precise, targeted delivery."
"Now, we are ready to bring this technology into clinical trials for advancing dose-dependent medicine. Kindeva stood out not only for their track record of supporting drug developers through the trial process, but for their history and shared commitment to making meaningful innovations widely accessible.”
Kindeva is committed to being a leader in the growing intranasal drug delivery space and sees RSH’s technology as a breakthrough innovation.
Kindeva's expertise in manufacturing and regulatory pathways will be crucial in RSH’s journey to receiving FDA approval, and its collaboration will extend the technology's global reach when it is eventually ready for commercial distribution.
Commenting on the partnership, David Stevens, Chief Commercial and Operating Officer at Kindeva, said: “Kindeva's proven expertise and track record of developing and commercializing novel drug delivery devices makes us the ideal partner to support Rocket Science Health’s new Olfactory device."
"I am incredibly excited to collaborate with the fantastic Rocket team as they look to realise their ambition to create a step change improvement in nasal drug delivery.”
